was read the article
array:24 [ "pii" => "S0021755715001217" "issn" => "00217557" "doi" => "10.1016/j.jped.2015.06.003" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "296" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "J Pediatr (Rio J). 2015;91 Supl 1:S11-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1224 "formatos" => array:3 [ "EPUB" => 80 "HTML" => 689 "PDF" => 455 ] ] "Traduccion" => array:1 [ "pt" => array:20 [ "pii" => "S2255553615001251" "issn" => "22555536" "doi" => "10.1016/j.jpedp.2015.09.007" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "296" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "J Pediatr (Rio J). 2015;91 Supl 1:S11-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2101 "formatos" => array:3 [ "EPUB" => 85 "HTML" => 1604 "PDF" => 412 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo de revisão</span>" "titulo" => "Chronic obstructive pulmonary diseases in children" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S11" "paginaFinal" => "S25" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Doenças pulmonares obstrutivas crônicas na criança" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1697 "Ancho" => 2502 "Tamanyo" => 321300 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Exacerbações pulmonares agudas bacterianas em doenças pulmonares obstrutivas crônicas na criança (DPOCC) e pneumonia em criança previamente saudável.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jose Dirceu Ribeiro, Gilberto Bueno Fischer" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jose Dirceu" "apellidos" => "Ribeiro" ] 1 => array:2 [ "nombre" => "Gilberto Bueno" "apellidos" => "Fischer" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0021755715001217" "doi" => "10.1016/j.jped.2015.06.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755715001217?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553615001251?idApp=UINPBA000049" "url" => "/22555536/00000091000006S1/v1_201511280546/S2255553615001251/v1_201511280546/pt/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S0021755715001308" "issn" => "00217557" "doi" => "10.1016/j.jped.2015.08.006" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "305" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "J Pediatr (Rio J). 2015;91 Supl 1:S26-35" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1252 "formatos" => array:3 [ "EPUB" => 79 "HTML" => 751 "PDF" => 422 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Insomnia in childhood and adolescence: clinical aspects, diagnosis, and therapeutic approach" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S26" "paginaFinal" => "S35" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Insônia na infância e adolescência: aspectos clínicos, diagnóstico e abordagem terapêutica" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Magda Lahorgue Nunes, Oliviero Bruni" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Magda Lahorgue" "apellidos" => "Nunes" ] 1 => array:2 [ "nombre" => "Oliviero" "apellidos" => "Bruni" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2255553615001330" "doi" => "10.1016/j.jpedp.2015.08.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553615001330?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755715001308?idApp=UINPBA000049" "url" => "/00217557/00000091000006S1/v1_201511300012/S0021755715001308/v1_201511300012/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S0021755715001199" "issn" => "00217557" "doi" => "10.1016/j.jped.2015.05.003" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "294" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "J Pediatr (Rio J). 2015;91 Supl 1:S2-S10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1185 "formatos" => array:3 [ "EPUB" => 83 "HTML" => 633 "PDF" => 469 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Update on the approach of urinary tract infection in childhood" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S2" "paginaFinal" => "S10" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Atualização da abordagem de infecção do trato urinário na infância" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Cristina Simões e Silva, Eduardo Araújo Oliveira" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ana Cristina" "apellidos" => "Simões e Silva" ] 1 => array:2 [ "nombre" => "Eduardo Araújo" "apellidos" => "Oliveira" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2255553615001263" "doi" => "10.1016/j.jpedp.2015.09.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553615001263?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755715001199?idApp=UINPBA000049" "url" => "/00217557/00000091000006S1/v1_201511300012/S0021755715001199/v1_201511300012/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Chronic obstructive pulmonary diseases in children" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S11" "paginaFinal" => "S25" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jose Dirceu Ribeiro, Gilberto Bueno Fischer" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Jose Dirceu" "apellidos" => "Ribeiro" "email" => array:2 [ 0 => "jdirceuribeiro@gmail.com" 1 => "dirceu.unicamp@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Gilberto Bueno" "apellidos" => "Fischer" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Department of Pediatrics, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Doenças pulmonares obstrutivas crônicas na criança" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1591 "Ancho" => 2500 "Tamanyo" => 258212 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Interactions of causes, effects, and clinical outcomes of chronic obstructive pulmonary disease in children (COPDC).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic obstructive pulmonary disease (COPD) is typically shown in the literature as evidence, in most cases, of the damage caused by smoking in adults older than 40 years. Without any direct and exclusive association with active long-term smoking, several chronic obstructive pulmonary diseases in children (COPDC) and adolescents progress with deterioration in lung structure and function, causing persistent (fixed) or intermittent (temporary) obstruction to pulmonary flow, secondary to genetic and/or environmental changes that cause airway inflammation and/or infection. Although the symptoms of COPDC are very similar, they have variable etiology, morbidity, physiopathology, prevalence, prognosis, genotypes, and phenotypes.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">While some COPDC have been the object of many studies, such as asthma, cystic fibrosis (CF), recurrent wheezing in infants (RWI), and bronchopulmonary dysplasia (BPD), others are known as “orphan diseases,” such as primary ciliary dyskinesia (PCD), non-cystic fibrosis bronchiectasis (NCFB), plastic bronchitis (PB), and bronchiolitis obliterans (BO).</p><p id="par0015" class="elsevierStylePara elsevierViewall">COPDC are characterized by high prevalence of asthma, RWI, and BPD, or low prevalence of BO, CF, PB, PCD, and NCFB. They are noncommunicable diseases, of long duration and slow progression, showing episodes of pulmonary exacerbation (PE), acute or permanent airflow limitation, and significant quality of life impairment.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> In all, the main pulmonary symptom is chronic cough, reflecting the presence of alterations in the airways, as there are no cough receptors in the alveoli. Another characteristic is the presence of bronchiectasis in many of them.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Most of them, including some of the several clinical forms of asthma, course with neutrophilic airway inflammation, which contributes to progressive worsening of pulmonary damage and function by releasing: (i) elastase: cleaves elastin and causes bronchiectasis, decreases opsonization and phagocytosis, increases secretion, decrease mucociliary clearance; (ii) DNA: increases the viscosity of secretions; (iii) hydrogen peroxide and other oxidants: causes tissue damage and inactivates α-1-antitrypsin; (iv) IL-8 and LTB4: attract more neutrophils.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Two aspects of COPDC have been thoroughly studied: the genetic component and environmental aggressions that initiate or exacerbate the diseases. Most COPDC show different genotypes, phenotypes, endotypes, and degrees of severity, require different types of management, and have no cure.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Pneumonia, BPD, BO, and/or RWI in the first years of life constitute risk groups for COPD in the long term and should receive medical follow-up and interventions to prevent the potential impact on long-term respiratory sequelae.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7–9</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">In all COPDC, PE is often triggered by viral and/or bacterial infections, pollution, and aeroallergens. The PE manifests as acute respiratory failure of varying intensity, both in asthma and RWI, and as increased cough and chronic infection in CF, BPD, NCFB, and PCD. The signs and symptoms of PE are more frequent and intense at nighttime.</p><p id="par0040" class="elsevierStylePara elsevierViewall">While the majority of acute respiratory diseases can be diagnosed easily and efficiently through history and physical examination, those with a chronic nature may require sophisticated laboratory tests. Continuous and scheduled evaluations by interdisciplinary health teams in specialized centers are required for effective management, better prognosis, and improved quality of life in COPDC.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Establishing protocols based on systematic reviews, meta-analyses, and guidelines allows for gaining control of the signs and symptoms of COPDC. Oral and (OC) inhaled corticosteroids (IC), mucolytics, bronchodilators, inhaled antibiotics, and other drugs should be used according to specific guidelines for each COPDC.</p><p id="par0050" class="elsevierStylePara elsevierViewall">While some groups of drugs are widely used, with variable degree of scientific evidence, such as bronchodilators and IC, others, such as long-term macrolide use, are more controversial. The use of macrolides in COPDC have been justified by the anti-inflammatory and immunomodulatory effect, the decrease in mucus production, and neutrophil elastase inhibition, in addition to reducing the production of pro-inflammatory mediators (<span class="elsevierStyleItalic">e.g.</span> IL8) and stimulating phagocytosis of apoptotic cells.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10–14</span></a> Although macrolides have shown to be effective in patients with CF and other COPDC, and have shown encouraging <span class="elsevierStyleItalic">in vitro</span> effects, their use in other COPDC has shown to be less effective and requires further studies.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">The objective of this review was to assess and describe the main events related to the diagnosis and management of COPDC, considering the physiopathology and interrelated genetic and environmental characteristics.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Data sources</span><p id="par0060" class="elsevierStylePara elsevierViewall">Review of the PubMed databases with selection of relevant references. The following descriptors were used (according to the MeSH criteria) related to each COPD included in the study: asthma, CF, RWI, BPD, PCD, NCFB, BO, and PB.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">COPDC: an overview</span><p id="par0065" class="elsevierStylePara elsevierViewall">The first important feature of COPDC is that their clinical manifestations and prevalence are more common in certain age groups, as shown in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>. The second is that interactions between the genetic component and environmental aggressions initiate or exacerbate them, as shown in <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>. The main differences and similarities between the COPDC are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. The third characteristic of COPDC is that they evolve with PE, predominantly infectious (CF), inflammatory (asthma), and mixed (asthma and viruses/bacteria).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">Infectious PE caused by bacteria are different in healthy children when compared with those with COPDC. <span class="elsevierStyleItalic">Streptococcus pneumoniae</span>, <span class="elsevierStyleItalic">Haemophilus influenzae</span> and <span class="elsevierStyleItalic">Staphylococcus aureus</span>, which have high virulence, are common causes of pneumonia in previously healthy individuals without COPDC and require treatment with low-spectrum antibiotics (<span class="elsevierStyleItalic">e.g.</span>, penicillin and amoxicillin), but cause short-term mortality. In contrast, many patients with COPDC, especially those with CF, PCD, and NCFB, have PE caused by low-virulence bacteria (<span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> (PA), <span class="elsevierStyleItalic">Burkholderia cepacia</span> complex, <span class="elsevierStyleItalic">Stenotrophomonas maltophilia</span> and, <span class="elsevierStyleItalic">Achromobacter xylosoxidans</span>), which cause long-term mortality; however, they require broad-spectrum antibiotics such as aminoglycosides, meropenem, and third-generation cephalosporins (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0075" class="elsevierStylePara elsevierViewall">Due to the characteristics of COPDC, several guidelines and systematic reviews for the diagnosis and management of the disease have been proposed for both periods between crises and PE of most COPDC, aiming to prevent further deterioration of pulmonary function and damage (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>).<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,15–27</span></a></p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Asthma</span><p id="par0080" class="elsevierStylePara elsevierViewall">Asthmatic individuals who manifested the disease early in life persist with symptoms, and evidence suggests that asthma severity in childhood predicts the disease severity in adulthood.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Recent guidelines emphasize difficulties for the definitive diagnosis of asthma in children younger than 5 years, where several COPDC phenotypes have been identified.</p><p id="par0085" class="elsevierStylePara elsevierViewall">For children older than 5 years, asthma diagnosis is based on: (1) a history of acute respiratory failure crises that improve with short-acting bronchodilators (SABA); (2) increased serum IgE in the absence of parasitic diseases, eosinophilia, and positive immediate hypersensitivity skin tests for airborne allergens; (3) spirometry and measurement of bronchial hyperresponsiveness (BHR) to methacholine challenge. The diagnosis can be made with the isolated presence and/or combination of the above items 1; 1<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>2; 1<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3; or 1<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>2<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>3.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Numerous factors have been associated with increased risk of developing asthma in adolescence, of which the following should be mentioned: personal or family history of allergy, male gender, obesity, pollution, exposure to cigarette smoke, RWI, severe infection by respiratory syncytial virus (RSV), pneumonia in the first year of life, RWI severity, altered pulmonary function, and BHR.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,29–31</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">There is no specific treatment for asthma, and it is preferable to use the term management for the tools used to attain disease control. The main objectives for outpatient management are: (i) make chronic symptoms minimal or nonexistent; (ii) decrease the intensity and the number of PE; (iii) maintain lung function as close as possible to normal levels; (iv) maintain normal levels of daily activities, including physical exercises; (v) prevent the adverse effects of anti-asthmatic drugs; (vi) prevent disease progression to irreversible airflow limitation; (vii) prevent asthma mortality.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,15–20</span></a> The main medications to control asthma are inhaled corticosteroids (IC).</p><p id="par0100" class="elsevierStylePara elsevierViewall">The classification of the clinical pictures and respective treatment steps are listed below:</p><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Steps in the treatment of asthma</span><p id="par0105" class="elsevierStylePara elsevierViewall">(Step 1) Individuals with intermittent asthma, characterized by normal spirometry and periods between crises lasting longer than 1 month without exacerbations in the last year, should receive SABA. (Step 2) Continued use of IC at low doses and rescue SABA during crisis. (Step 3) Continued use of low doses of IC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>long-acting beta agonists (LABA) with SABA for crises or IC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>formoterol for both maintenance and control. (Step 4) IC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>formoterol for maintenance and crises or medium or high doses of IC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>LABA and SABA, if necessary. (Step 5) Refer patient to a center specialized in asthma treatment for difficult-to-control disease: consider oral steroids and anti-IgE (omalizumab). Consider oral corticosteroids in severe PE and if the patient had previous severe PE.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,15–20</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Medications and steps are modified to the next step or revert to the previous step, depending on whether or not the asthma is controlled. A decrease in management steps must occur if the asthma is well controlled for at least 3 months.</p><p id="par0115" class="elsevierStylePara elsevierViewall">It is essential to verify at all consultations, whether the asthma is controlled or not, from the clinical and/or functional point of view, based on six parameters: (i) nocturnal signs and symptoms; (ii) daytime signals and symptoms; (iii) signs and symptoms with physical exercise or limitation in daily activities; (iv) PE; (v) need for relief medication (SABA); (vi) changes in lung function. Hence, asthma is considered controlled when all parameters are normal; it should be classified as partially controlled in the presence of one or two altered parameters; and finally, non-controlled asthma should be considered when three or more parameters are altered.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The absence of control of signs and symptoms, frequent exacerbations, previous admission to an intensive care unit (ICU), low values of forced expiratory volume in 1<span class="elsevierStyleHsp" style=""></span>s (FEV1), exposure to tobacco smoke, and need to use high-dose medications are characteristics associated with increased risk of adverse events in the future. By definition, an exacerbation at any week is indicative of non-controlled asthma and also of the need for review of the maintenance treatment.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16,17</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">In the management of patients with asthma, the following are essential: (i) management supported by evidence-based medicine; (ii) to perform the diagnosis and, if possible, the phenotype (<span class="elsevierStyleItalic">e.g</span>., allergic and non-allergic); (iii) to exclude and treat comorbidities; (iv) to assess and recommend the adequate use of prescribed drugs; (v) to assess, advise, and encourage treatment adherence; (vi) to assess and advise about environmental prophylaxis; (vii) to assess and advise on the triggering factors; (viii) to educate patient's caregivers about asthma and the factors influencing it; (ix) to give instructions on the adequate use of devices for administration of metered-dose and dry powder inhalers; (x) instructions for patients to be able to recognize when asthma control is deteriorating and what medications to use, when it occurs; (xi) to identify non-controlled patients and causes of lack of control; (xii) to advise that inhaled medications should be used with spacers; (xiii) to advise on the hygiene of spacers, which must be washed and left to soak in water with detergent; (xiv) LABA must not be used in children younger than 4 years; (xv) SABA are the agents of choice in PE; (xvi) IC alone or associated with bronchodilators are the basis of asthma treatment; (xvii) children younger than 6 years can use inhaled medication with spacer and those older than 6 years can use dry powder inhalers; (xviii) to assess pulmonary function regularly; (xix) to advise on the need for long-term medical care; (xx) omalizumab should be prescribed in reference centers for the management of patients with difficult-to-control asthma.</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Recurrent wheezing in infants (RWI)</span><p id="par0130" class="elsevierStylePara elsevierViewall">There are several phenotypes and risk factors (RF) for RWI, creating difficulties for asthma diagnosis and resulting in an excessive assessment for comorbidities.<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32–37</span></a> The main RF include: presence of familial and/or personal allergy, early sensitization, severe RSV infection, maternal smoking during pregnancy, and unfavorable airway geometry. Other implicated RF are: genetic variants, excessive hygiene, Western lifestyle, pollution, gastroesophageal reflux disease (GERD), low socioeconomic status, urban environment, antibiotic use, diet, few siblings, ethnicity, male gender, and attendance of daycare.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Exposure to maternal smoking, both intrauterine and in the early years of life, has contributed to increased incidence and severity of childhood and adult asthma, COPD in adults, lung function deficits, lung hypoplasia, respiratory tract infections, and higher predisposition to sudden death syndrome.<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">39–41</span></a> Respiratory viruses are the main RF for asthma and RWI initiation or exacerbation: (i) some viruses initiate asthma; (ii) the more severe the respiratory infection, the higher the likelihood of developing asthma; (iii) viruses cause PE in children and adults with established asthma.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">The diagnosis of asthma in infants is a major challenge for clinicians; to attain a diagnosis with a high degree of suspicion, the presence of allergy should be investigated, as it is a persistent asthma predictor. The investigation of severe COPDC in children younger than 5 years may require many tests, including high-resolution computed tomography (HRCT), lung function assessment, cellular and humoral immunity evaluation, bronchoscopy, bronchoalveolar lavage, 24-h esophageal pH-metry, endobronchial biopsy, mutation screening, and sodium and chloride sweat measurements.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> In contrast, no investigation is necessary for most of RWI, because it cannot differentiated with certainty whether the future course of the RWI will be persistent asthma or transient wheezing.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Some asthma predictive indices (APIs) have been developed to identify children with RWI and at risk for asthma after 6 years of age (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">38,44</span></a> Some authors have mentioned methodological and practical limitations of APIs, suggesting that they have low capacity and poor sensitivity to predict asthma at school age,<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45,46</span></a> and that although they are simple and easy-to-apply tools, they have not been sufficiently validated. According to these authors, predicting asthma using simple clinical models is virtually impossible.<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45,46</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0150" class="elsevierStylePara elsevierViewall">Although most of the scientific community is favorable to the use of APIs,<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">47,48</span></a> the search for clinical and/or laboratory markers for the diagnosis of asthma in RWI and children younger than 5 years remains a rich area for future studies. Infants and preschoolers with RWI or asthma have less PE, and show symptom and lung function improvement when treated with IC.<a class="elsevierStyleCrossRefs" href="#bib0245"><span class="elsevierStyleSup">49–51</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">The dosages of the main IC used in COPDC are shown in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>.</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Bronchiolitis obliterans (BO)</span><p id="par0160" class="elsevierStylePara elsevierViewall">Bronchiolitis obliterans (BO) is a predominantly neutrophilic COPDC with high levels of proinflammatory cytokines, bronchial remodeling, and fibrosis in the small airways. When the etiology is infectious, it is called post-infectious BO (PIBO). Most often, PIBO is caused by previous infection caused by adenovirus, but influenza, measles, RSV, and <span class="elsevierStyleItalic">Mycoplasma pneumoniae</span> are also observed. Latin American countries have the highest rates of this disease.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27,52–62</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Studies have shown that lung function remains altered with an obstructive pattern and air trapping during childhood. These patients are often hospitalized due to recurrent respiratory infections. Patients show slight improvement over the years.<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">54,62</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">Five criteria are essential for the diagnosis of PIBO: (i) history of acute viral bronchiolitis and viral pneumonia before the age of 3; (ii) evidence of persistent airway obstruction after the acute event, identified by physical examination and/or lung function, which is not responsive to at least 2 weeks of systemic corticosteroids associated with bronchodilator; (iii) radiological findings of obstruction such as hyperinflation, atelectasis, bronchial wall thickening, and bronchiectasis; (iv) mosaic perfusion and air trapping on HRCT; (v) exclusion of other COPDC.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27,60</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">Among the causes of BO are: drugs, association with Stevens–Johnson syndrome, collagenoses, irradiation, foreign body or gastric content aspiration, and graft <span class="elsevierStyleItalic">vs.</span> host disease after transplantation.</p><p id="par0180" class="elsevierStylePara elsevierViewall">The definitive diagnosis of BO is made through anatomopathological examination of fragments obtained from lung biopsy. BO is classified as: (i) proliferative BO, characterized by airway obstruction by polyps and/or granulation tissue in the lumen of bronchioles; or (ii) constrictive BO, characterized by peribronchial inflammation and fibrosis.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">58</span></a> As the lung biopsy is an invasive test, most studies perform the diagnosis based on clinical history and HRCT, spirometry, and perfusion scintigraphy with technetium. Alterations in HRCT include wall thickening and bronchiole obliteration and, with the disease progression, bronchiectasis, bronchial wall thickening, mosaic perfusion, air trapping, reduced lung volume, and decreased diameter of hilar and peripheral vessels are observed.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27,59</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">There is no specific treatment for BO. Oxygen therapy is essential in some patients, mainly after ICU discharge for severe acute viral bronchiolitis (AVB) and in patients who develop chronic hypoxemia. Contact prophylaxis with intra and extra-domestic pollutants, reduction of exposure to active and passive smoking, and anti-pneumococcal and influenza vaccination are important steps for BO management. In the early phases of the disease, some patients may benefit from systemic corticosteroid therapy. Bronchodilators, antibiotics in infectious exacerbations, surgery for resection of fixed collapsed lung, and lung transplant have also been used.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Primary ciliary dyskinesia (PCD)</span><p id="par0190" class="elsevierStylePara elsevierViewall">Primary ciliary dyskinesia (PCD) is an autosomal recessive COPDC caused by several alterations in airway cilia anatomical and functional structure, resulting in inflammation and infection, with an incidence of 1:4000–40,000 live births. Laterality defects in the thoraco-abdominal organs occur in about 50% of patients with PCD, and most have <span class="elsevierStyleItalic">situs inversus totalis</span> (Kartagener syndrome).<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">24,63–66</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">PCD should be suspected in children with: (i) <span class="elsevierStyleItalic">situs inversus totalis</span> or other laterality defect in thoraco-abdominal organs; (ii) recurrent upper (otitis, sinusitis) and lower respiratory tract infections (pneumonia, abscesses) and chronic respiratory tract diseases of undefined etiology (bronchiectasis, chronic cough, atelectasis, and middle lobe syndrome); (iii) neonatal respiratory distress syndrome of undefined causes; (iv) diagnosis of PCD in other family members; (v) congenital heart disease, especially if associated with heterotaxia, and with chronic and repeated infections of the lower and upper airways.<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">24,67</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Clinical manifestations and alterations in PCD vary according to age<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a>: in the prenatal period, ultrasound may reveal mild fetal cerebral ventriculomegaly, heterotaxia and <span class="elsevierStyleItalic">situs inversus totalis</span> (approximately 25% of individuals with <span class="elsevierStyleItalic">situs inversus totalis</span> have PCD). PCD prevalence in patients with heterotaxia remains unknown. In the neonatal period, 75% of full-term newborns with PCD have respiratory distress, requiring supplemental oxygen for days or weeks. Some have continuous rhinorrhea, heterotaxia, and hydrocephalus.</p><p id="par0205" class="elsevierStylePara elsevierViewall">During childhood, chronic productive cough is observed, in association with atelectasis and/or recurrent pneumonia, atypical asthma that does not respond to treatment, bronchiectasis, NCFB, nasal polyps, chronic rhinosinusitis, hearing impairment, and chronic otitis. In adolescence and adulthood, bronchiectasis, chronic mucopurulent sputum, digital clubbing, spirometry with progressive or mixed obstructive ventilatory pattern, nasal polyposis, and halitosis can be observed, as well as infertility in men (50%) and ectopic pregnancy in women.</p><p id="par0210" class="elsevierStylePara elsevierViewall">Diagnosis is based on clinical and radiological alterations, nasal nitric oxide levels, ciliary beat pattern at video microscopy, structural alterations of the cilia by electron microscopy, and detection of mutations. Only 50–60% of PCD patients have a known mutation.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25,68,69</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">CF evolves with secondary ciliary dyskinesia, whereas in PCD it is primary; the management of pulmonary disease in these two diseases is virtually identical.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Cystic fibrosis (CF)</span><p id="par0220" class="elsevierStylePara elsevierViewall">CF is an autosomal recessive disease caused by mutations in the CFTR (cystic fibrosis transmembrane regulator) gene, 7q31.2 region, which has more than 2000 identified mutations, divided into six classes regarding the production and function of the CFTR protein. The qualitative or quantitative absence or dysfunction of CFTR causes physiopathological changes in several organs. Most of CF morbidity and mortality is caused by manifestations in the respiratory and digestive tracts.<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">70–73</span></a></p><p id="par0225" class="elsevierStylePara elsevierViewall">It is currently known that in Class I, II, and III mutations, the disease starts before symptom onset, constituting a major factor for early intervention and more aggressive treatments, showing promising results in reducing lung function damage and deterioration, with consequent increased survival.<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">70–73</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">Availability of newborn screening, sweat testing, CFTR gene mutation screening, medications, and possible use of correctors, enhancers, and stabilizers (for some mutations) of the CFTR protein are concrete facts in the last decade. The consequence is that the survival of these patients is increasingly higher.<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">73</span></a> Lung damage and decreased lung function are progressive, and depend on the mutation, gender, polymorphisms, treatment availability and adherence, early treatment, comorbidities, and care in reference centers.<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">74–76</span></a></p><p id="par0235" class="elsevierStylePara elsevierViewall">The physiopathology of COPD in CF can be understood with the following six events (6D): (i) defect in the CFTR gene; (ii) impairment or absence of the CFTR protein; (iii) dehydration of the airway surface liquid; (iv) defect in bacterial clearance in the airways; (v) secondary ciliary dyskinesia; (vi) destruction of the airway epithelium.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">77</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">To attain the diagnosis of CF after neonatal screening, alterations in the gene and or CFTR protein should be verified. The CFTR gene is studied through the analysis of mutations and polymorphisms. The CFTR protein function and/or presence can be assessed in the sweat glands (sweat test, evaporimetry, difference of potential, and pH) nasal epithelium, salivary glands, and digestive tract.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">78,79</span></a></p><p id="par0245" class="elsevierStylePara elsevierViewall">Diagnosing or ruling out CF is not always easy, even after comprehensive testing, particularly in adolescents and adults with classes IV, V, and VI mutations, which cause non-classical forms and are often associated with rare mutations, threshold levels of chloride in sweat, late-onset clinical manifestations, and atypical symptoms.<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">80</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall">As CF affects many organs, its management is complex. The service must have interdisciplinary teams with several health care professionals, physical therapy, medical examinations, frequent visits to the hospital, and use of daily, repetitive medications, which are sometimes complicated and costly.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">81</span></a></p><p id="par0255" class="elsevierStylePara elsevierViewall">Patients with CF are highly susceptible to chronic lung infection by PA. PA acquisition occurs very early and is related to lung function deterioration and worse CF prognosis; hence, intensive treatment against PA is crucial in the management of CF.</p><p id="par0260" class="elsevierStylePara elsevierViewall">Other bacteria frequently found in the airways of CF patients and that determine the lung function damage and deterioration include <span class="elsevierStyleItalic">S. aureus</span>, <span class="elsevierStyleItalic">H. influenzae</span>, PA, <span class="elsevierStyleItalic">B. cepacia</span> complex, <span class="elsevierStyleItalic">S. maltophilia</span>, and <span class="elsevierStyleItalic">Achromobacter species</span>. Non-tuberculous <span class="elsevierStyleItalic">Mycobacteria</span> (NTM) and other anaerobic bacteria and fungi are found less frequently, and tend to appear at the more advanced stages of lung disease.<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">82,83</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">Inhaled antibiotics (IA) are essential for the treatment of chronic lung infections in CF. The increased survival in patients with CF in recent decades can be partly attributed to the use of IA. They have higher deposition at the infection site and less risk of systemic side effects than parenteral therapy, decrease PE, and improve quality of life and spirometry.<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">84,85</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall">CF patients with chronic lung infection by PA should receive long-term, nebulized anti-pseudomonal therapy, unless there is contraindication. Among the IA, tobramycin and colistin are currently available, while aztreonam, levofloxacin, and liposomal amikacin will soon be available.<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">86</span></a> The administration of IA is time-consuming and is a heavy burden for patients. Treatment adherence is a significant challenge.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">87</span></a></p><p id="par0275" class="elsevierStylePara elsevierViewall">The treatment of the first acquisition episode, from infection to chronic infection and PE due to PA, are reasons for debates and controversies in the literature.<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">88</span></a></p><p id="par0280" class="elsevierStylePara elsevierViewall">PA eradication protocols have demonstrated antibiotic efficacy in the first bacterial isolation; intensive treatment with intravenous antibiotics in PE and IA in the periods between crises.<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">89–91</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">It is advisable to perform lung damage assessment by HRCT at least every 2 years, and pulmonary function assessment by spirometry at least twice a year.</p><p id="par0290" class="elsevierStylePara elsevierViewall">IA, anti-inflammatory drugs, corticosteroids, bronchodilators, and mucolytics may be necessary for the management of lung disease in CF. Auxiliary measures have shown benefits with respiratory physical therapy, regular exercise, avoiding indoor and outdoor pollution, and active and passive smoking. It is crucial to include treatment adherence measures and continuity of care for life. Visits to the reference center must be monthly during the first year and at least four times a year until adulthood.</p><p id="par0295" class="elsevierStylePara elsevierViewall">Adherence to CF management varies between 35 and 75% and is lower in adolescence. Poor adherence to medication worsens lung function, increases the frequency of PE, and results in a larger number of consultations, hospitalizations, and costs. Therefore, interventions are necessary to improve medication adherence.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">81</span></a></p><p id="par0300" class="elsevierStylePara elsevierViewall">Many international organizations have proposed that the management of lung disease in CF should be directed by guidelines based on scientific evidence. Thus, recent publications on the management of COPD in CF can be found, and represent the “state-of-the-art” for CF reference centers.<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">82,83,91,92</span></a></p><p id="par0305" class="elsevierStylePara elsevierViewall">Recently, advances in the treatment of CF have gained prominence. Mutations in the CFTR gene have been widely identified, and the highest prevalence of the F508del mutation has been emphasized. Treatment for the specific mutation and/or class of mutations has focused on the study of new drugs. Two drugs have been used in studies considering the F508del mutation in homozygous form, and results of the association of ivacaftor (increases opening of the chloride channel – potentiator) and lumacaftor (increases protein number in the epithelium – potentiator) have shown increased chloride transport when compared with the values of the individual drugs.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">93</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Bronchopulmonary dysplasia (BPD)</span><p id="par0310" class="elsevierStylePara elsevierViewall">BPD is a secondary COPDC, and is associated with prematurity and risk factors (RF) related to it. Low birth weight, high fraction of inspired oxygen, patent ductus arteriosus, high intravenous fluid volume values, mechanical ventilation with high pressures, genetic susceptibility, and infection in the neonatal period contribute to the prevalence and severity of BPD. This disease affects approximately 30% of newborns with birth weight less than 1500<span class="elsevierStyleHsp" style=""></span>g.<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">94,95</span></a></p><p id="par0315" class="elsevierStylePara elsevierViewall">Several studies have shown that most infants who develop BPD evolve with lung function alterations throughout life.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,96–101</span></a></p><p id="par0320" class="elsevierStylePara elsevierViewall">Similar to all COPDC, BPD has no specific treatment. Regarding the advances to reduce mortality in the neonatal period, in recent decades, three factors have clearly proven to be effective: (i) corticosteroid administration to pregnant women with high-risk pregnancies; (ii) administration of surfactants to premature infants; (iii) less aggressive ventilation strategies.<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">102,103</span></a></p><p id="par0325" class="elsevierStylePara elsevierViewall">The following have also been used: diuretics (furosemide); bronchodilators; systemic corticosteroids and IC; vitamin A; methylxanthines (pentoxifylline, caffeine); pulmonary vasodilators (sildenafil, inhaled nitric oxide); late surfactant administration; and antioxidants (superoxide dismutase), with varying degrees of efficacy in the management of acute and/or chronic BPD. However, there is little evidence of the beneficial actions of most of these agents when used in short- or long-term management of BPD.<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">102,103</span></a></p><p id="par0330" class="elsevierStylePara elsevierViewall">BPD is associated with a high incidence of pulmonary arterial hypertension (PAH). Treatment with sildenafil has been associated with significant improvement in echocardiographic markers of PAH and reduced need for oxygen. The drug is well tolerated.<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">104</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Bronchiectasis related to diseases other than CF (NCFB)</span><p id="par0335" class="elsevierStylePara elsevierViewall">Bronchiectasis is an alteration that accompanies many COPDC. It may be associated with and complicate asthma, PCD, CF, BO, and NCFB, and be consequent to measles, pertussis, immunodeficiency, allergic bronchopulmonary aspergillosis, inflammatory bowel disease, rheumatoid arthritis, foreign body inhalation, PCD, BO, respiratory tract malformation (<span class="elsevierStyleItalic">e.g.</span>: tracheoesophageal fistula, congenital cystic adenomatoid malformation) and result from inflammatory and infectious diseases to the airways. NCFB encompasses several etiologies and degrees of severity; a clear cause cannot be established in many patients.<a class="elsevierStyleCrossRefs" href="#bib0525"><span class="elsevierStyleSup">105,106</span></a></p><p id="par0340" class="elsevierStylePara elsevierViewall">Pulmonary disease in NCFB is very similar to CF, BO, and PCD. The challenge a child with NCFB faces is the pursuit of a diagnosis. The management is very similar to that of most COPDC and should be considered on a case-by-case basis, aiming at patient comfort and clinical response.<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">107</span></a></p><p id="par0345" class="elsevierStylePara elsevierViewall">Although some randomized, controlled, double-blind trials have shown that prolonged use of macrolides in patients with NCFB improves quality of life and reduces PE rates, the role of macrolides in NCFB management remains unclear and they cannot be recommended for routine use. Until very recently, these drugs were investigated in small trials of short duration, which did not evaluate relevant clinical outcomes, such as PE and quality of life.</p><p id="par0350" class="elsevierStylePara elsevierViewall">Long-term oral antibiotics should not be routinely prescribed. Macrolides (or other antibiotics) can be considered for a limited period of 12–24 months, especially in patients with frequent exacerbations.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,108,109</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Plastic bronchitis (PB)</span><p id="par0355" class="elsevierStylePara elsevierViewall">PB is a rare COPDC with unknown prevalence and etiology, with formation of bronchial molds of gelatinous or solid appearance in the large airways, whose composition varies, consisting of mucins, fibrin, DNA, or eosinophils, depending on the PB etiology. The diseases most often associated with PB are congenital heart disease and asthma. It has also been described in infection by influenza virus, H1N1, lymphatic diseases, allergic bronchopulmonary aspergillosis, and sickle-cell disease.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">109</span></a> Although bronchodilators, corticosteroids, antibiotics, mucolytics, physical therapy, antifibrinolytic therapy with heparin, and urokinase have been used, single or repeat bronchoscopy is essential for diagnosis and treatment.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Final considerations</span><p id="par0360" class="elsevierStylePara elsevierViewall">The pediatrician's actions are vital for the management of COPDC. The clinician should suspect the disease in the presence of signs and symptoms in order to attain an early and accurate diagnosis, know the risk factors and associated comorbidities, and assess treatment adherence, the correct use of prescribed drugs, and their side effects based on well-defined management protocols, preferably based on specific guidelines.</p><p id="par0365" class="elsevierStylePara elsevierViewall">Management benefits should be assessed through the reduction in acute pulmonary exacerbations, increased quality of life, and decreased evolution of lung function loss (spirometry, measurement of oxygen saturation, lung clearance index) and lung damage (HRCT every 2 years, if necessary). Therefore, the sequential evaluation of lung function and damage should be standardized and continuous, throughout life. For most COPDC, monitoring in specialized reference centers by interdisciplinary teams leads to better outcomes.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflicts of interest</span><p id="par0370" class="elsevierStylePara elsevierViewall">The authors declare no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:19 [ 0 => array:3 [ "identificador" => "xres583830" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Sources" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Summary of the findings" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec600021" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres583829" "titulo" => "Resumo" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Fonte dos dados" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Síntese dos dados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusões" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec600020" "titulo" => "Palavras-chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Data sources" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "COPDC: an overview" ] 7 => array:3 [ "identificador" => "sec0020" "titulo" => "Asthma" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Steps in the treatment of asthma" ] ] ] 8 => array:2 [ "identificador" => "sec0030" "titulo" => "Recurrent wheezing in infants (RWI)" ] 9 => array:2 [ "identificador" => "sec0035" "titulo" => "Bronchiolitis obliterans (BO)" ] 10 => array:2 [ "identificador" => "sec0040" "titulo" => "Primary ciliary dyskinesia (PCD)" ] 11 => array:2 [ "identificador" => "sec0045" "titulo" => "Cystic fibrosis (CF)" ] 12 => array:2 [ "identificador" => "sec0050" "titulo" => "Bronchopulmonary dysplasia (BPD)" ] 13 => array:2 [ "identificador" => "sec0055" "titulo" => "Bronchiectasis related to diseases other than CF (NCFB)" ] 14 => array:2 [ "identificador" => "sec0060" "titulo" => "Plastic bronchitis (PB)" ] 15 => array:2 [ "identificador" => "sec0065" "titulo" => "Final considerations" ] 16 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflicts of interest" ] 17 => array:2 [ "identificador" => "xack196381" "titulo" => "Acknowledgements" ] 18 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-05-07" "fechaAceptado" => "2015-06-16" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec600021" "palabras" => array:3 [ 0 => "Child" 1 => "Chronic obstructive pulmonary disease" 2 => "Chronic cough" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec600020" "palabras" => array:3 [ 0 => "Criança" 1 => "Doença pulmonar obstrutiva crônica" 2 => "Tosse crônica" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To verify and describe the main events related to the diagnosis and management of chronic obstructive pulmonary diseases in children (COPDC) and adolescents, considering the interrelated physiopathology, genetic, and environmental characteristics.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Sources</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Relevant literature from PubMed was selected and reviewed.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Summary of the findings</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">COPDC have an environmental and/or genetic origin and its manifestation has manifold genotypes, phenotypes, and endotypes. Although COPDC has no cure, it can be clinically controlled. Chronic cough is the main symptom and bronchiectasis can be present in several COPDC patients. The management of COPDC is more effective if based on guidelines and when treatment regimen adherence is promoted. Oral and inhaled corticosteroids, bronchodilators, inhaled antibiotics, and treatment of pulmonary exacerbation (PE) are the bases of COPDC management, and should be individualized for each patient.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Correct diagnosis and knowledge of risk factors and comorbidities are essential in COPDC management. Procedures and drugs used should be based on specific guidelines for each COPDC case. Treatment adherence is critical to obtain the benefits of management. COPDC clinical control must be evaluated by the decrease in PEs, improved quality of life, reduction of pulmonary function loss, and lung structural damage. For most cases of COPDC, monitoring by interdisciplinary teams in specialized reference centers with surveillance strategies and continuous care leads to better outcomes, which must be evaluated by decreasing pulmonary function damage and deterioration, better prognosis, better quality life, and increased life expectancy.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objectives" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Sources" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Summary of the findings" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "pt" => array:3 [ "titulo" => "Resumo" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Verificar e descrever os principais eventos relacionados ao diagnóstico e manejo das doenças pulmonares obstrutivas crônicas em crianças (DPOCC) e adolescentes, tendo em vista a fisiopatologia, características genéticas e ambientais inter-relacionadas.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Fonte dos dados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Revisão na base de dado PUBMED com seleção de referências relevantes.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Síntese dos dados</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">As DPOCC têm origem ambiental e/ou genética e se manifestam com diversos genótipos, fenótipos e endótipos e, embora possam ser controladas, não têm cura. O principal sintoma é a tosse crônica e muitas cursam com bronquiectasia. O manejo tem maior eficácia se baseado em <span class="elsevierStyleItalic">guidelines</span> e se a adesão ao regime terapêutico for estimulada e comprovada. Corticóides orais e inalatórios, broncodilatadores, antibióticos inalados e tratamento das exacerbações pulmonares (EP) são vigas mestras do manejo e devem ser individualizados para cada DPOCC.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusões</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Nas DPOCC é fundamental o diagnóstico correto, conhecer os fatores de risco e comorbidades. Os procedimentos e os medicamentos devem ser baseados em <span class="elsevierStyleItalic">guidelines</span> específicos para cada DPOCC. Adesão ao tratamento é fundamental para obter os benefícios do manejo. O controle deve ser avaliado pela diminuição das EP, melhora na qualidade de vida e redução da evolução da perda da função e dano estrutural pulmonar. Para a maioria das DPOCC, o acompanhamento por equipes interdisciplinares em centros de referência especializados, com estratégias de vigilância e acolhimento contínuos, conduz a melhores desfechos que devem ser avaliados pela diminuição da deterioração do dano e da função pulmonar, melhor prognóstico, melhor qualidade de vida e aumento da expectativa de vida.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivos" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Fonte dos dados" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Síntese dos dados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusões" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Ribeiro JD, Fischer GB. Chronic obstructive pulmonary diseases in children. J Pediatr (Rio J). 2015;91:S11–25.</p>" ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1686 "Ancho" => 2500 "Tamanyo" => 153195 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Age of onset and higher prevalence of major chronic obstructive pulmonary disease in children (COPDC) compared with chronic obstructive pulmonary disease (COPD) in adults. CF, cystic fibrosis; RWIs, recurrent wheezing in infants; BPD, bronchopulmonary dysplasia; PCD, primary ciliary dyskinesia; NCFB, non-cystic fibrosis bronchiectasis; PB, plastic bronchitis; BO, bronchiolitis obliterans; m, month; y, year.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1591 "Ancho" => 2500 "Tamanyo" => 258212 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Interactions of causes, effects, and clinical outcomes of chronic obstructive pulmonary disease in children (COPDC).</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1694 "Ancho" => 2500 "Tamanyo" => 305400 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Bacterial acute pulmonary exacerbations in chronic obstructive pulmonary disease in children (COPDC) and pneumonia in previously healthy children.</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1927 "Ancho" => 2500 "Tamanyo" => 323447 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Control or non-control of chronic obstructive pulmonary disease in children (COPDC) based on diagnosis.</p>" ] ] 4 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">?, unknown; ABPA, allergic bronchopulmonary aspergillosis; IA, inhaled antibiotics; BD, bronchodilator; NCFB, non-cystic fibrosis bronchiectasis; BO, bronchiolitis obliterans; PIBO, post-infectious bronchiolitis obliterans; PB, plastic bronchitis; CHD, congenital heart disease; IC, inhaled corticosteroids; CD4, CD4 molecule; CD8, CD8 molecule; CFTR, cystic fibrosis transmembrane regulator; BPD, bronchopulmonary dysplasia; PCD, primary ciliary dyskinesia; COPD, chronic obstructive pulmonary disease; COPDC, chronic obstructive pulmonary disease in childhood; GERD, gastroesophageal reflux disease; PE, pulmonary exacerbation; CF, cystic fibrosis; GM-CSF, granulocyte macrophage-colony stimulating factor; PH, pulmonary hypertension; IgE immunoglobulin E; IL, interleukin; API, asthma predictor index; URTI, upper respiratory tract infection; LABA, long-acting beta-agonists; BAL, bronchoalveolar lavage; LTB4 leukotriene B4; M, mild; Mo, moderate; S, severe; MMP, matrix metallopeptidase; NF-kB, NF-kappaB; VLBW, very low birth weight; RSV, respiratory syncytial virus; RV, rhinovirus; SABA, short-acting beta agonists; RWI, recurrent wheezing in infants; HRCT, high-resolution computed tomography; SPT, skin prick test; TGF, transforming growth factor; IRT, immunoreactive trypsinogen; NBS, newborn screening test; TNF, tumor necrosis factor; RSV, respiratory syncytial virus.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">COPDC characteristics \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">ASTHMA \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">RWIs \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">BPD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">BO and PIBO \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CF \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">BP \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">PCD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">NCFB \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Classic adult COPD \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptom onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Before 5 years of life \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Newborn \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><3 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2 years in classical forms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">CHD: <5 yearsAsthma: >5 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">First year of life \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">After the second year of life \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Adults >40 years \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age of higher prevalence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Childhood \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1–2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">First year of life \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Childhood and adolescence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Up to 30 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">CHD: <5 yearsAsthma: >5 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Childhood and adolescence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Childhood and adolescence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">After 40 years \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Main clinical marker \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Family history of asthma, personal atopy and positive response to BD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Infection by respiratory viruses(RSV and RV) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PrematurityOxygen use \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Virus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Chronic colonization of the airways by Pseudomonas aeruginosa and pancreatic failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Elimination of bronchial casts with sputum \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Suppurative infections of the upper and lower airways \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Recurrent infections and chronic cough \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Smoking, emphysema, and biomass smoke \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Prevalence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High(5–30%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High(15–60%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High; 26% in VLBW infants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low. Classified as rare disease. 1:2500–1:10,000 live births \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6–15.8% of the population older >40 years \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Bases for diagnosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Spirometry, positive response to BD, IgE, and skin prick test \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>3 episodes of wheezing in infancy and positive API \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prematurity and oxygen therapy for more than 28 days in early life \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Lung biopsy, HRCT and lung perfusion scintigraphy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NBS with a positive IRT, chloride >60<span class="elsevierStyleHsp" style=""></span>mEq/L in sweat, two mutations in the CFTR gene \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Airway cast expectoration and bronchoscopy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Dextrocardia, chronic sinusitis, pneumonia and recurrent URTIs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">HRCT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Smoking, emphysema and alpha1 antitrypsin deficiency \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Genotype \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Many chromosomes and polymorphisms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Many chromosomes and polymorphisms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Little known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Little known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Autosomal recessive with alterations in CFTR gene located on chromosome 7.6 classes of mutations. Many polymorphisms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Autosomal recessive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Phenotype \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Several \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Several \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">M, Mo, S \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Constrictive proliferative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Many. With and without pancreatic failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depending on the etiology, the bronchial mold has a different composition \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">With and without dextrocardia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">With and without asthma \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BAL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Eosinophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils and/or eosinophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mucin and fibrin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Neutrophils and macrophages \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Markers in lymphocytes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High CD4/CD8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Varies whether the BAL is eosinophilic or neutrophilic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High CD8/CD4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Inflammatory mediators \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IL4, IL5, IL9, IL13, TNF-α, GM-CSF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Varies whether the BAL is eosinophilic or neutrophilic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">TNF-α, IL-1, IL-6, IL-10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IL1β, IL6, IL8, TNF-α, and NFkβ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IL8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IL8, LTB4, proteases, MMP9, TNF-α, TGF-β1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Main causes of PE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses and aero-allergens \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Gram-negative bacteria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">InfluenzaH1N1? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses and bacteria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bacteria and viruses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Viruses and bacteria \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Response to BD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Little known \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Obstruction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Intermittent in the mild cases and fixed in severe cases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Intermittent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Intermittent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Fixed \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Survival/Mortality \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Long/low \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Long/low \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the severity and gestational age \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on severity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><40 years – class I–III mutations.>40 years – class IV–VI mutations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Low/high \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><40 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the age of onset and etiology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Depends on the severity.High mortality in the elderly \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Evolution to restrictive lung diseases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Frequent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Frequent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Frequent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Frequent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Frequent \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Evolution to lung transplantation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rare \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Comorbidities \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Allergic rhinitis, atopic dermatitis and GERD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">GERD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">GERD and prematurity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Severe adenovirus infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Pancreatic failure, depression, diabetes, and osteoporosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">CHD, asthma, lymphatic disease, ABPA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Azoospermia and chronic rhinosinusitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Asthma and GERD \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IC; SABA; LABA; Montelukast; omalizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IC; SABA; Montelukast \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IC; SABA;Sildenafil and PHDiuretics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IC; SABA; LABA; corticoids; oxygen; tiotropium bromide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mucolytics; IA; digestive enzymes, IC; SABA; LABA; corticosteroids;tiotropium; Oxygen \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">bronchoscopy; mucolytics and antifibrinolytics \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mucolytics, IA; IC; SABA; LABA; corticosteroids and oxygen \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mucolytics; IA IC; SABA; LABA; corticosteroids; oxygen; macrolides \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">IC; SABA; LABA; corticosteroids; Tiotropium and oxygen \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Perspectives \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Early intervention <span class="elsevierStyleItalic">in utero</span> and early in life at risk populations. Prophylaxis against RSV and RV.Immunomodulation with prebiotics, probiotics and bacterial lysates.Prevention of allergic sensitization. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Permissive hypercapnia and improved care to VLBW infants \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Palivizumab; genes and polymorphisms; respiratory virus vaccines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Corrections by potentiators and carriers of CFTR protein and new tests for the diagnosis of atypical forms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Multicenter studies, national registries \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic studies and early diagnosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Prophylaxis against viruses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Avoid smokingAsthma control \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab952473.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Main clinical and pathophysiological characteristics of COPDC <span class="elsevierStyleItalic">versus</span> COPD in adults.</p>" ] ] 5 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">API, asthma predictive index.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">API criteria \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Original API<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Modified API<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="2" align="left" valign="middle">General</td><td class="td" title="table-entry " align="left" valign="top">Convincing API: more than three episodes of wheezing/year during the first 3 years of life with a major criterion or two minor. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " rowspan="2" align="left" valign="middle">The child must have a history of four or more episodes of wheezing. At least one episode verified and confirmed by a physician.</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Less convincing API: less than three episodes of wheezing/year during the first 3 years of life with a major criterion or two minor. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Major \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">History of parental asthmaAtopic dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">History of parental asthmaAtopic dermatitis diagnosed by physicianAllergic sensitization to one or more aeroallergens \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Minor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Allergic rhinitis diagnosed by physicianWheezing unrelated to coldsEosinophilia<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>4% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sensitization to cow's milk, egg, or peanutWheezing unrelated to coldsEosinophilia<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>4% \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab952472.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Asthma Predictive Index (API) by Castro-Rodriguez et al.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> and Guilbert et al.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a></p>" ] ] 6 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Inhaled corticosteroids \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Daily doses in children younger than 5 years</th><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Daily doses (6–11 years)</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Low \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Medium \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">High \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Low \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Medium \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">High \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Beclomethasone Dipropionate HFA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">50–100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>100–200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>200 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Budesonide spray \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100–200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>200–400 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>400 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Nebulized budesonide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">250–500 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>500–1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">250–500 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>500–1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>1000 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Fluticasone propionate HFA spray \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100–200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>250–500 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>500 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Fluticasone propionate dry powder \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100–200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>250–400 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>400 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ciclesonide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">160 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>80–160 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>160 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mometasone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">There are no studies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">110 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">220<span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>440 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">440 or more \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Triamcinolone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">There are no studies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">400–800 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">>800–1200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>1200 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab952474.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Low, medium, and high daily doses of inhaled corticosteroids (IC) in asthma (Global Initiative for Asthma – GINA) and in chronic obstructive pulmonary disease in childhood.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:109 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early origins of chronic obstructive lung diseases across the life course" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10654-014-9981-5" "Revista" => array:6 [ "tituloSerie" => "Eur J Epidemiol" "fecha" => "2014" "volumen" => "29" "paginaInicial" => "871" "paginaFinal" => "885" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The chronic obstructive pulmonary disease–asthma overlap syndrome" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Allergy Asthma Proc" "fecha" => "2015" "volumen" => "36" "paginaInicial" => "112" "paginaFinal" => "118" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Pharm Des" "fecha" => "2014" "volumen" => "20" "paginaInicial" => "1" "paginaFinal" => "17" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Med J Aust" "fecha" => "2015" "volumen" => "202" "paginaInicial" => "21" "paginaFinal" => "23" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of inflammation in the pathophysiology of CF lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1385/CRIAI:23:1:005" "Revista" => array:6 [ "tituloSerie" => "Clin Rev Allergy Immunol" "fecha" => "2002" "volumen" => "23" "paginaInicial" => "5" "paginaFinal" => "23" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1398-9995.2008.01640.x" "Revista" => array:6 [ "tituloSerie" => "Allergy" "fecha" => "2008" "volumen" => "63" "paginaInicial" => "5" "paginaFinal" => "34" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long term sequelae from childhood pneumonia; systematic review and meta analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0031239" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e31239" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pneumonia in childhood and impaired lung function in adults: a longitudinal study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2014-3060" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2015" "volumen" => "135" "paginaInicial" => "607" "paginaFinal" => "616" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New BPD predicts lung function at school age: follow-up study and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.23153" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2015" "volumen" => "50" "paginaInicial" => "1090" "paginaFinal" => "1098" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term macrolide treatment for chronic respiratory disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00136712" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2013" "volumen" => "42" "paginaInicial" => "239" "paginaFinal" => "251" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azithromycin: mechanisms of action and their relevance for clinical applications" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pharmthera.2014.03.003" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Ther" "fecha" => "2014" "volumen" => "143" "paginaInicial" => "225" "paginaFinal" => "245" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is there a role for macrolides in severe asthma?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MCP.0000000000000017" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pulm Med" "fecha" => "2014" "volumen" => "20" "paginaInicial" => "95" "paginaFinal" => "102" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pharmthera.2009.06.004" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Ther" "fecha" => "2009" "volumen" => "124" "paginaInicial" => "86" "paginaFinal" => "95" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2012-202698" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2013" "volumen" => "68" "paginaInicial" => "322" "paginaFinal" => "329" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "International European Respiratory Society/American Thoracic Society guidelines on severe asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00102714" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2014" "volumen" => "44" "paginaInicial" => "1377" "paginaFinal" => "1378" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Global Strategy for Asthma Management and Prevention. Available from: <a href="http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf">http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf</a> [cited 26.03.15]." ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diretrizes da Sociedade Brasileira de Pneumologia e Tisiologia para o manejo da asma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2012" "volumen" => "38" "paginaInicial" => "S1" "paginaFinal" => "S46" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British guideline on the management of asthma – a national clinical guideline [Revised]" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2014" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "British guideline on the management of asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Thorax" "fecha" => "2014" "volumen" => "69" "paginaInicial" => "S1" "paginaFinal" => "S192" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Diagnosis and management of asthma in children 5 years and younger. A guide for health care professionals [Revised]" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2014" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Clinical guidelines for the care of children with cystic fibrosis 2014 – Royal Brompton Hospital" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "edicion" => "6th ed." "fecha" => "2014" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200812-1845PP" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2009" "volumen" => "180" "paginaInicial" => "802" "paginaFinal" => "808" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary exacerbations in cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.20023" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2004" "volumen" => "37" "paginaInicial" => "400" "paginaFinal" => "406" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of primary ciliary dyskinesia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13630-014-0011-8" "Revista" => array:5 [ "tituloSerie" => "Cilia" "fecha" => "2015" "volumen" => "4" "paginaInicial" => "2" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00176608" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2009" "volumen" => "34" "paginaInicial" => "1264" "paginaFinal" => "1276" "link" => array:1 [ …1] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug therapy for the prevention and treatment of bronchopulmonary dysplasia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fphar.2015.00012" "Revista" => array:5 [ "tituloSerie" => "Front Pharmacol" "fecha" => "2015" "volumen" => "6" "paginaInicial" => "12" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post-infectious bronchiolitis obliterans in children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pediatr (Rio J)" "fecha" => "2011" "volumen" => "87" "paginaInicial" => "187" "paginaFinal" => "198" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Changes in the prevalence of asthma in adults since 1966: the Busselton health study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00194308" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2010" "volumen" => "35" "paginaInicial" => "273" "paginaFinal" => "278" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The origins of asthma and chronic obstructive pulmonary disease in early life" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/pats.200808-092RM" "Revista" => array:6 [ "tituloSerie" => "Proc Am Thorac Soc" "fecha" => "2009" "volumen" => "6" "paginaInicial" => "272" "paginaFinal" => "277" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long term sequelae from childhood pneumonia; systematic review and metaanalysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0031239" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e31239" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of infection in the development and exacerbation of asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/ers.09.60" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Respir Med" "fecha" => "2010" "volumen" => "4" "paginaInicial" => "71" "paginaFinal" => "83" "link" => array:1 [ …1] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phenotypic expressions of childhood wheezing and asthma: implications for therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pediatrics" "fecha" => "2011" "volumen" => "158" "paginaInicial" => "878" "paginaFinal" => "884" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What lessons can be learned about asthma phenotypes in children from cohort studies?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pai.12359" "Revista" => array:6 [ "tituloSerie" => "Pediatr Allergy Immunol" "fecha" => "2015" "volumen" => "26" "paginaInicial" => "300" "paginaFinal" => "305" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammatory phenotypes in stable and acute childhood asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.prrv.2011.04.007" "Revista" => array:6 [ "tituloSerie" => "Paediatr Respir Rev" "fecha" => "2011" "volumen" => "12" "paginaInicial" => "165" "paginaFinal" => "169" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Investigation of young children with severe recurrent wheeze: any clinical benefit?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.06.00030605" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2006" "volumen" => "27" "paginaInicial" => "29" "paginaFinal" => "35" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiological aspects of and risk factors for wheezing in the first year of life" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1590/S1806-37132014000600005" "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2014" "volumen" => "40" "paginaInicial" => "617" "paginaFinal" => "625" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EISL Study Group International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2009.115188" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2010" "volumen" => "65" "paginaInicial" => "1004" "paginaFinal" => "1009" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2004" "volumen" => "114" "paginaInicial" => "6" ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Smoking and asthma. Review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3122/jabfm.2011.03.100180" "Revista" => array:6 [ "tituloSerie" => "J Am Board Fam Med" "fecha" => "2011" "volumen" => "24" "paginaInicial" => "313" "paginaFinal" => "322" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of parental smoking on lung function and development during infancy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Respirology" "fecha" => "2003" "volumen" => "8" "paginaInicial" => "266" "paginaFinal" => "285" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(10)61388-8" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2011" "volumen" => "377" "paginaInicial" => "139" "paginaFinal" => "146" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of viral respiratory infections in asthma and asthma exacerbations" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(10)61380-3" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2010" "volumen" => "376" "paginaInicial" => "826" "paginaFinal" => "834" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Asthma and wheezing in the first six years of life" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199501193320301" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1995" "volumen" => "332" "paginaInicial" => "133" "paginaFinal" => "138" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A clinical index to define risk of asthma in young children with recurrent wheezing" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.162.4.9912111" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2000" "volumen" => "162" "paginaInicial" => "1403" "paginaFinal" => "1406" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predicting persistence of asthma in preschool wheezers: crystal balls or muddy waters?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.prrv.2012.08.004" "Revista" => array:6 [ "tituloSerie" => "Paediatr Respir Rev" "fecha" => "2013" "volumen" => "14" "paginaInicial" => "46" "paginaFinal" => "52" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The asthma predictive index: not a useful tool in clinical practice" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2010.10.012" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2010" "volumen" => "127" "paginaInicial" => "293" "paginaFinal" => "294" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utility of the Asthma Predictive Index in predicting childhood asthma and identifying disease-modifying interventions" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.anai.2013.12.001" "Revista" => array:6 [ "tituloSerie" => "Ann Allergy Asthma Immunol" "fecha" => "2014" "volumen" => "112" "paginaInicial" => "188" "paginaFinal" => "190" "link" => array:1 [ …1] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The necessity of having asthma predictive scores in children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2013.09.006" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2013" "volumen" => "132" "paginaInicial" => "1311" "paginaFinal" => "1313" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term inhaled corticosteroids in preschool children at high risk for asthma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa051378" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2006" "volumen" => "354" "paginaInicial" => "1985" "paginaFinal" => "1997" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2008-2867" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2009" "volumen" => "123" "paginaInicial" => "e519" "paginaFinal" => "e525" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of inhaled corticosteroids in wheezy infants/preschoolers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rmed.2012.10.010" "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "2013" "volumen" => "107" "paginaInicial" => "153" "paginaFinal" => "154" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2005.044909" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2006" "volumen" => "61" "paginaInicial" => "503" "paginaFinal" => "506" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5-year follow-up" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.20472" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2006" "volumen" => "41" "paginaInicial" => "947" "paginaFinal" => "953" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary function of a paediatric cohort of patients with post infectious bronchiolitis obliterans. A long term follow-up" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2014-205328" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2015" "volumen" => "70" "paginaInicial" => "169" "paginaFinal" => "174" "link" => array:1 [ …1] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Airway inflammation in children and adolescents with bronchiolitis obliterans" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cyto.2014.10.026" "Revista" => array:6 [ "tituloSerie" => "Cytokine" "fecha" => "2015" "volumen" => "73" "paginaInicial" => "156" "paginaFinal" => "162" "link" => array:1 [ …1] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical prediction rule to diagnose post-infectious bronchiolitis obliterans in children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.21080" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2009" "volumen" => "44" "paginaInicial" => "1065" "paginaFinal" => "1069" "link" => array:1 [ …1] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histology of childhood bronchiolitis obliterans" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.10097" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2002" "volumen" => "33" "paginaInicial" => "466" "paginaFinal" => "474" "link" => array:1 [ …1] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia and diffuse panbronchiolitis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Chest Med" "fecha" => "1993" "volumen" => "14" "paginaInicial" => "611" "paginaFinal" => "622" "link" => array:1 [ …1] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-resolution computed tomography in pediatric patients with postinfectious bronchiolitis obliterans" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Thorac Imaging" "fecha" => "1999" "volumen" => "14" "paginaInicial" => "85" "paginaFinal" => "89" "link" => array:1 [ …1] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post infectious bronchiolitis obliterans in children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.prrv.2010.07.005" "Revista" => array:6 [ "tituloSerie" => "Paediatr Respir Rev" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "233" "paginaFinal" => "239" "link" => array:1 [ …1] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical guide for diagnosis and care of children and adolescents with post-infectious bronchiolitis obliterans" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Chil Enf Respir" "fecha" => "2009" "volumen" => "25" "paginaInicial" => "141" "paginaFinal" => "163" ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary function in children and adolescents with postinfectious bronchiolitis obliterans" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Bras Pneumol" "fecha" => "2010" "volumen" => "36" "paginaInicial" => "453" "paginaFinal" => "459" "link" => array:1 [ …1] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary ciliary dyskinesia: diagnostic and phenotypic features" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200303-365OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2004" "volumen" => "169" "paginaInicial" => "459" "paginaFinal" => "467" "link" => array:1 [ …1] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High prevalence of primary ciliary dyskinesia in a British Asian population" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/adc.2009.158493" "Revista" => array:6 [ "tituloSerie" => "Arch Dis Child" "fecha" => "2010" "volumen" => "95" "paginaInicial" => "51" "paginaFinal" => "52" "link" => array:1 [ …1] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary ciliary dyskinesia: recent advances in diagnostics, genetics, and characterization of clinical disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201301-0059CI" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2013" "volumen" => "188" "paginaInicial" => "913" "paginaFinal" => "922" "link" => array:1 [ …1] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Presentation of primary ciliary dyskinesia in children: 30 years’ experience" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jpc.12791" "Revista" => array:6 [ "tituloSerie" => "J Paediatr Child Health" "fecha" => "2015" "volumen" => "51" "paginaInicial" => "722" "paginaFinal" => "726" "link" => array:1 [ …1] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early lung disease in young children with primary ciliary dyskinesia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.20792" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2008" "volumen" => "43" "paginaInicial" => "514" "paginaFinal" => "516" "link" => array:1 [ …1] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Picking up speed: advances in the genetics of primary ciliary dyskinesia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/pr.2013.200" "Revista" => array:6 [ "tituloSerie" => "Pediatr Res" "fecha" => "2014" "volumen" => "75" "paginaInicial" => "158" "paginaFinal" => "164" "link" => array:1 [ …1] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0345" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.201305-110OC" "Revista" => array:6 [ "tituloSerie" => "Ann Am Thorac Soc" "fecha" => "2013" "volumen" => "10" "paginaInicial" => "574" "paginaFinal" => "581" "link" => array:1 [ …1] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0350" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Origins of cystic fibrosis lung disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra1300109" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "372" "paginaInicial" => "351" "paginaFinal" => "362" "link" => array:1 [ …1] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0355" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Children and young adults with CF in the USA have better lung function compared with the UK" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2014-205718" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2015" "volumen" => "70" "paginaInicial" => "229" "paginaFinal" => "236" "link" => array:1 [ …1] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0360" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2466-15-3" "Revista" => array:5 [ "tituloSerie" => "BMC Pulm Med" "fecha" => "2015" "volumen" => "15" "paginaInicial" => "3" "link" => array:1 [ …1] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0365" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2012-201747" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2012" "volumen" => "67" "paginaInicial" => "874" "paginaFinal" => "881" "link" => array:1 [ …1] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0370" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk factors for bronchiectasis in children with cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1301725" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "368" "paginaInicial" => "1963" "paginaFinal" => "1970" "link" => array:1 [ …1] ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0375" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201004-0643OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2010" "volumen" => "182" "paginaInicial" => "1251" "paginaFinal" => "1261" "link" => array:1 [ …1] ] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0380" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Airway remodelling and its relationship to inflammation in cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2009.134106" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2011" "volumen" => "66" "paginaInicial" => "624" "paginaFinal" => "629" "link" => array:1 [ …1] ] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0385" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.21044" "Revista" => array:6 [ "tituloSerie" => "Pediatr Pulmonol" "fecha" => "2009" "volumen" => "44" "paginaInicial" => "503" "paginaFinal" => "511" "link" => array:1 [ …1] ] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib0390" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-230X-13-91" "Revista" => array:5 [ "tituloSerie" => "BMC Gastroenterol" "fecha" => "2013" "volumen" => "13" "paginaInicial" => "91" "link" => array:1 [ …1] ] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib0395" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Measurements of CFTR-mediated Cl-secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0047708" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2012" "volumen" => "7" "paginaInicial" => "e47708" "link" => array:1 [ …1] ] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib0400" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2013-203832" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2014" "volumen" => "69" "paginaInicial" => "254" "paginaFinal" => "260" "link" => array:1 [ …1] ] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib0405" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of medication adherence on lung health outcomes in cystic fibrosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MCP.0b013e3283659f45" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pulm Med" "fecha" => "2013" "volumen" => "19" "paginaInicial" => "687" "paginaFinal" => "691" "link" => array:1 [ …1] ] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib0410" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.201405-203AS" "Revista" => array:6 [ "tituloSerie" => "Ann Am Thorac Soc" …5 ] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib0415" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant <span class="elsevierStyleItalic">Staphylococcus aureus</span>, Gram-negative bacteria, and multiple infections" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.201402-050AS" "Revista" => array:6 [ …6] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib0420" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CF pulmonary guidelines: chronic medications for maintenance of lung health" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200705-664OC" "Revista" => array:6 [ …6] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib0425" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early intervention and prevention of lung disease in CF: a European consensus" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcf.2004.03.008" "Revista" => array:6 [ …6] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib0430" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cystic fibrosis microbiology: advances in antimicrobial therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcf.2015.02.005" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib0435" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety, efficacy and convenience of tobramycin inhalation powder (TIP™) in CF patients. The EAGER trial" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib0440" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differences in prevalence and treatment of <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> in cystic fibrosis centers in Denmark, Norway and Sweden" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib0445" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparative efficacy and safety of 4 randomized regimens to treat early <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> infection in children with cystic fibrosis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archpediatrics.2011.136" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib0450" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of early <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> infection in patients with cystic fibrosis: the ELITE trial" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thx.2009.121657" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib0455" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines committee cystic fibrosis foundation pulmonary guideline – pharmacologic approaches to prevention and eradication of initial <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> infection" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1513/AnnalsATS.201404-166OC" "Revista" => array:6 [ …6] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib0460" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib0465" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1409547" "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib0470" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib0475" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk factors for bronchopulmonary dysplasia in very low birth weight newborns treated with mechanical ventilation in the first week of life" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/tropej/fmi051" "Revista" => array:6 [ …6] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib0480" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung function among infants born preterm, with or without bronchopulmonary dysplasia" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.21609" "Revista" => array:6 [ …6] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib0485" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Respiratory symptoms at age 8 years in a cohort of very low birth weight children" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib0490" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200912-1806OC" "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib0495" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Obstructive pulmonary disease in old age among individuals born preterm" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10654-013-9761-7" "Revista" => array:6 [ …6] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib0500" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of preterm birth on later FEV1: a systematic review and meta-analysis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2012-203079" "Revista" => array:6 [ …6] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib0505" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00039513" "Revista" => array:6 [ …6] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib0510" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug therapy for the prevention and treatment of associated pulmonary hypertension: a retrospective study of efficacy and safety" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib0515" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib0520" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00431-015-2515-7" "Revista" => array:6 [ …6] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib0525" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The etiologies of non-CF bronchiectasis in childhood: a systematic review of 989 subjects" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2431-14-1" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib0530" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Non-CF bronchiectasis: clinical and HRCT evaluation" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ppul.10289" "Revista" => array:6 [ …6] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib0535" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New therapeutic options for non-cystic fibrosis bronchiectasis" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QCO.0000000000000147" "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib0540" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)60953-2" "Revista" => array:6 [ …6] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib0545" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plastic bronchitis: new insights and a classification scheme" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.prrv.2005.09.001" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack196381" "titulo" => "Acknowledgements" "texto" => "<p id="par0375" class="elsevierStylePara elsevierViewall">To Professor Dr. Paulo Augusto Moreira Camargos for his encouragement, suggestions, and manuscript review. To Professor Dr. Fernando Augusto de Lima Marson, for the excellent chart contributions, text reading, suggestions, and appraisals. To the Pediatric Pneumology Team of Universidade Estadual de Campinas (Unicamp), for their constant help in the management of COPDC for many years: Adyleia Aparecida Dalbo Contrera Toro, Maria Angela Gonçalves de Oliveira Ribeiro, Andressa Peixoto, Milena Baptistela Grotta, Emilia Gonçalves, and Maria Cristina Simões Ferreira.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/00217557/00000091000006S1/v1_201511300012/S0021755715001217/v1_201511300012/en/main.assets" "Apartado" => array:4 [ "identificador" => "10176" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00217557/00000091000006S1/v1_201511300012/S0021755715001217/v1_201511300012/en/main.pdf?idApp=UINPBA000049&text.app=https://jped.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755715001217?idApp=UINPBA000049" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 7 | 8 | 15 |
2024 October | 152 | 58 | 210 |
2024 September | 71 | 62 | 133 |
2024 August | 75 | 91 | 166 |
2024 July | 140 | 79 | 219 |
2024 June | 138 | 51 | 189 |
2024 May | 95 | 28 | 123 |
2024 April | 91 | 44 | 135 |
2024 March | 131 | 30 | 161 |
2024 February | 93 | 34 | 127 |
2024 January | 62 | 45 | 107 |
2023 December | 42 | 40 | 82 |
2023 November | 93 | 43 | 136 |
2023 October | 43 | 39 | 82 |
2023 September | 53 | 46 | 99 |
2023 August | 38 | 25 | 63 |
2023 July | 41 | 30 | 71 |
2023 June | 39 | 21 | 60 |
2023 May | 37 | 30 | 67 |
2023 April | 42 | 15 | 57 |
2023 March | 57 | 42 | 99 |
2023 February | 34 | 21 | 55 |
2023 January | 31 | 23 | 54 |
2022 December | 57 | 25 | 82 |
2022 November | 37 | 32 | 69 |
2022 October | 61 | 30 | 91 |
2022 September | 38 | 25 | 63 |
2022 August | 37 | 46 | 83 |
2022 July | 39 | 31 | 70 |
2022 June | 35 | 30 | 65 |
2022 May | 175 | 33 | 208 |
2022 April | 124 | 45 | 169 |
2022 March | 59 | 40 | 99 |
2022 February | 25 | 32 | 57 |
2022 January | 26 | 20 | 46 |
2021 December | 40 | 21 | 61 |
2021 November | 14 | 12 | 26 |
2021 October | 25 | 24 | 49 |
2021 September | 19 | 13 | 32 |
2021 August | 15 | 13 | 28 |
2021 July | 15 | 7 | 22 |
2021 June | 16 | 11 | 27 |
2021 May | 22 | 24 | 46 |
2021 April | 43 | 20 | 63 |
2021 March | 33 | 7 | 40 |
2021 February | 18 | 5 | 23 |
2021 January | 25 | 5 | 30 |
2020 December | 33 | 11 | 44 |
2020 November | 33 | 12 | 45 |
2020 October | 40 | 14 | 54 |
2020 September | 30 | 16 | 46 |
2020 August | 23 | 2 | 25 |
2020 July | 33 | 6 | 39 |
2020 June | 31 | 6 | 37 |
2020 May | 31 | 2 | 33 |
2020 April | 14 | 9 | 23 |
2020 March | 15 | 6 | 21 |
2020 February | 30 | 4 | 34 |
2020 January | 26 | 13 | 39 |
2019 December | 20 | 4 | 24 |
2019 November | 12 | 5 | 17 |
2019 October | 18 | 13 | 31 |
2019 September | 18 | 10 | 28 |
2019 August | 15 | 10 | 25 |
2019 July | 17 | 5 | 22 |
2019 June | 37 | 11 | 48 |
2019 May | 12 | 6 | 18 |
2019 April | 17 | 13 | 30 |
2019 March | 15 | 6 | 21 |
2019 February | 11 | 11 | 22 |
2019 January | 15 | 4 | 19 |
2018 December | 11 | 11 | 22 |
2018 November | 8 | 3 | 11 |
2018 October | 17 | 9 | 26 |
2018 September | 6 | 6 | 12 |
2018 August | 4 | 4 | 8 |
2018 July | 8 | 4 | 12 |
2018 June | 10 | 17 | 27 |
2018 May | 13 | 20 | 33 |
2018 April | 8 | 4 | 12 |
2018 March | 9 | 2 | 11 |
2018 February | 6 | 4 | 10 |
2018 January | 8 | 1 | 9 |
2017 December | 1 | 4 | 5 |
2017 November | 7 | 3 | 10 |
2017 October | 6 | 2 | 8 |
2017 September | 7 | 2 | 9 |
2017 August | 2 | 1 | 3 |
2017 July | 0 | 4 | 4 |
2017 June | 12 | 17 | 29 |
2017 May | 18 | 2 | 20 |
2017 April | 7 | 6 | 13 |
2017 March | 7 | 47 | 54 |
2017 February | 4 | 4 | 8 |
2017 January | 5 | 3 | 8 |
2016 December | 9 | 7 | 16 |
2016 November | 7 | 6 | 13 |
2016 October | 12 | 9 | 21 |
2016 September | 10 | 5 | 15 |
2016 August | 5 | 2 | 7 |
2016 July | 10 | 4 | 14 |
2016 June | 8 | 7 | 15 |
2016 May | 24 | 18 | 42 |
2016 April | 17 | 12 | 29 |
2016 March | 18 | 7 | 25 |
2016 February | 13 | 9 | 22 |
2016 January | 19 | 17 | 36 |
2015 December | 16 | 17 | 33 |
2015 November | 29 | 16 | 45 |
2015 October | 40 | 17 | 57 |
2015 September | 10 | 8 | 18 |